Nuvalent Insider Trade: Cashless Option Exercise Keeps 63K-Share Holding
Rhea-AI Filing Summary
Nuvalent, Inc. (NUVL) – Form 4 insider transaction summary
Chief Scientific Officer Henry E. Pelish reported a series of option exercises and related open-market sales executed on 06/25/2025 and 06/27/2025 under a Rule 10b5-1 trading plan adopted on 11/01/2024.
- Options exercised (Code “M”): 10,800 Class A shares in four tranches – 3,677 and 347 shares at a $27.85 strike (options granted 01/06/2023) and 4,953 and 1,823 shares at a $29.33 strike (options granted 03/01/2023).
- Shares sold (Code “S”): 10,800 Class A shares at weighted-average prices of $79.87 (range $79.80-$79.92) on 06/25/2025 and $79.92 (range $79.80-$80.00) on 06/27/2025.
- Ownership impact: Pelish’s direct Class A common-stock holding remains unchanged at 63,101 shares after the paired exercise-and-sell transactions, indicating a cashless exercise structure.
- Remaining derivative holdings: 28,328 options at a $27.85 strike (expiring 01/06/2033) and 25,299 options at a $29.33 strike (expiring 03/01/2033) are still outstanding.
No new shares were added to, or removed from, insider ownership; the activity primarily generated liquidity while maintaining the existing equity stake. Investors typically view such neutral, plan-based sales as having limited informational content, though they can add modest selling pressure near the $80 trading level.
Positive
- Executive retains 63,101 Class A shares after transactions, maintaining significant alignment with shareholders.
- Compliance with Rule 10b5-1 demonstrates proactive governance and reduces insider-trading risk.
Negative
- Sale of 10,800 shares around $80 may add short-term supply and could be perceived as partial profit-taking.
Insights
TL;DR: Neutral cashless exercise; insider stake unchanged, ~$80 sale price shows valuation level but no directional signal.
The Form 4 details paired option exercises and immediate sales, a classic cashless exercise. Pelish unlocked the intrinsic value of 10,800 options (strike $27.85–$29.33) by selling an equal number of shares at roughly $79.9, realising a spread of about $50 per share. Because beneficial ownership stayed at 63,101 shares, there is no dilution or new insider accumulation. The trades were executed under a pre-planned Rule 10b5-1 program, reducing signalling risk. From a market perspective, the $0.9 million sale could create minor supply but does not suggest a change in insider conviction. Overall impact on valuation or thesis is neutral.
TL;DR: Rule 10b5-1 plan reduces governance concern; activity routine, modest liquidity event.
The disclosure confirms compliance with updated Rule 10b5-1 affirmative-defense requirements, including plan adoption date. The option tranches vest monthly over four-year periods, aligning executive incentives with long-term performance. No red flags emerge: the executive retains a sizeable 63k-share stake and 53k options. Because transactions were pre-scheduled, they carry low litigation or perception risk. I assess the governance impact as negligible.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 347 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 1,823 | $0.00 | -- |
| Exercise | Class A Common Stock | 347 | $27.85 | $10K |
| Exercise | Class A Common Stock | 1,823 | $29.33 | $53K |
| Sale | Class A Common Stock | 2,170 | $79.92 | $173K |
| Exercise | Stock Option (Right to Buy) | 3,677 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 4,953 | $0.00 | -- |
| Exercise | Class A Common Stock | 3,677 | $27.85 | $102K |
| Exercise | Class A Common Stock | 4,953 | $29.33 | $145K |
| Sale | Class A Common Stock | 8,630 | $79.87 | $689K |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.80 to $79.92, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.80 to $80.00, inclusive. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. The shares underlying this option have vested or shall vest over the four years following March 1, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
